**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77154

**Manuscript Type:** LETTER TO THE EDITOR

**Comment on “Posterior reversible encephalopathy syndrome in a patient with metastatic breast cancer: A case report”**

Kunić S *et al*. Comment: PRES in metastatic breast cancer

Suljo Kunić, Omer Ć Ibrahimagić, Biljana Kojić, Dževad Džananović

**Suljo Kunić,** Department of Neurology, Primary Health Center Tuzla, Tuzla 75000, Bosnia and Herzegovina

**Omer Ć Ibrahimagić, Biljana Kojić,** Department of Neurology, University Clinical Center Tuzla, Tuzla 75000, Bosnia and Herzegovina

**Dževad Džananović,** Department of Physical Medicine and Rehabilitation, Primary Health Center Tuzla, Tuzla 75000, Bosnia and Herzegovina

**Author contributions:** Kunić S and Ibrahimagić OĆ designed the commentary; Kunić S, Kojić B and Džananović Dž performed the data analysis and wrote the letter; and Ibrahimagić OĆ revised the letter for important intellectual content

**Corresponding author: Suljo Kunić, PhD, Assistant Professor,** Department of Neurology, Primary Health Center Tuzla, Albina i Franje Herljevica br 1, Tuzla 75000, Bosnia and Herzegovina. suljo.kunic@hotmail.com

**Received:** April 26, 2022

**Revised:** June 13, 2022

**Accepted:** July 24, 2022

**Published online:** August 26, 2022

**Abstract**

Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state, manifesting clinical symptoms of headache, altered consciousness, visual disturbances, and seizures. Although several diseases have been identified as causative of PRES, the underlying mechanism remains unclear. Song *et al* recently published “Posterior reversible encephalopathy syndrome (PRES) in a patient with metastatic breast cancer: A case report“ in the *World Journal of Clinical Cases*, highlighting and discussing the role of hypercalcemia in PRES as related to uncontrolled hypertension. To build upon this case description, we provide further insight into the possible underlying mechanisms of PRES through this commentary.

**Key Words:** Case report; Hypercalcemia; Paraneoplastic syndrome; Posterior reversible encephalopathy syndrome

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Kunić S, Ibrahimagić OĆ, Kojić B, Džananović D. Comment on “Posterior reversible encephalopathy syndrome in a patient with metastatic breast cancer: A case report”. *World J Clin Cases* 2022; 10(24): 8805-8807

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i24/8805.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i24.8805

**Core Tip:** We speculate that posterior reversible encephalopathy syndrome may be caused by paraneoplastic antibodies, tumors or even antitumor therapy, per se, in addition to the hypercalcemia postulated by Song *et al* in “Posterior reversible encephalopathy syndrome (PRES) in a patient with metastatic breast cancer: A case report“ (*World Journal of Clinical Cases*, March 2022).

**TO THE EDITOR**

We read the article “Posterior reversible encephalopathy syndrome (PRES) in a patient with metastatic breast cancer: A case report“, written by colleagues Song *et al*[1] and published in the March online issue of *World Journal of Clinical Cases*, with great interest. We now welcome the opportunity to make a short comment, as this very interesting article assumes the role of hypercalcemia in PRES by causing uncontrolled hypertension.

With regard to the 51-year-old woman with PRES-related hypercalcemia described in the Case Report, we agree with authors’ insight that there are various possible causes of the neurological symptom of high-level serum calcium. In a similar Case Report by Mirian *et al*[2], a 74-year-old woman with PRES is described with elevations in serum calcium associated with this syndrome; her imaging abnormalities completely resolved after the serum calcium returned to normal. There is also the case of a 38-year-old woman with breast tumor reported by Camara-Lemarroy *et al*[3]; for this patient, the treating physicians considered the physiopathological mechanisms of malignant hypercalcemia (14.5 mg/dL) that can lead to neurological symptoms corresponding to PRES. Ultimately, all 3 cases support the role of hypercalcemia in PRES.

However, Barber *et al*[4] have clinical experience with PRES presenting in a 58-year-old woman with ovarian cancer in the presence of paraneoplastic antibodies (namely, antibodies to collapsin response-mediator protein-5), detected in cerebrospinal fluid. This association may point to another cause for this condition[4]. There is also a patient case of delayed gemcitabine-induced PRES described in the literature by Schaub and Tang[5].

It is a well-known fact that malignant tumors can cause activation of endothelial cells, proliferation and neovascularization, all which lead to vascular cerebral dysregulation. We speculate, thusly, that PRES may be caused by paraneoplastic antibodies, tumors or even antitumor therapy, *per se*, in addition to the hypercalcemia postulated by Song *et al*[1]. In this regard, we suggest that clinicians addressing similar cases in the future should include screening for paraneoplastic syndrome and parathyroid hormone changes in their clinical investigations. Since treatment success and overall prognosis are related to the underlying etiology, solidifying our knowledge of such on a case-by-case basis will benefit this patient population overall.

**REFERENCES**

1 **Song CH**, Lee SJ, Jeon HR. Posterior reversible encephalopathy syndrome in a patient with metastatic breast cancer: A case report. *World J Clin Cases* 2022; **10**: 2281-2285 [PMID: 35321170 DOI: 10.12998/wjcc.v10.i7.2281]

2 **Mirian A**, Le C, Sharma M, Budhram A, Markovic N. Hypercalcemia-Associated Posterior Reversible Encephalopathy Syndrome. *Neurohospitalist* 2021; **11**: 373-374 [PMID: 34539967 DOI: 10.1177/19418744211000974]

3 **Camara-Lemarroy CR**, Gonzalez-Moreno EI, Ortiz-Corona Jde J, Yeverino-Castro SG, Sanchez-Cardenas M, Nuñez-Aguirre S, Villarreal-Alarcon MA, Galarza-Delgado DA. Posterior reversible encephalopathy syndrome due to malignant hypercalcemia: physiopathological considerations. *J Clin Endocrinol Metab* 2014; **99**: 1112-1116 [PMID: 24476076 DOI: 10.1210/jc.2013-3487]

4 **Barber E**, Nugzar R, Finkelshtein V, Puzhevsky A, Levy T. Posterior reversible encephalopathy syndrome case report in an untreated, normotensive, ovarian cancer patient in the presence of paraneoplastic antibodies. *BMC Neurol* 2020; **20**: 330 [PMID: 32878599 DOI: 10.1186/s12883-020-01913-y]

5 **Schaub JR**, Tang SC. Delayed Gemcitabine-Induced Posterior Reversible Encephalopathy Syndrome. *Am J Med Sci* 2021; **361**: 795-798 [PMID: 33888263 DOI: 10.1016/j.amjms.2020.10.030]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 26, 2022

**First decision:** June 8, 2022

**Article in press:** July 24, 2022

**Specialty type:** Clinical neurology

**Country/Territory of origin:** Bosnia and Herzegovina

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chen C, China; Shiraishi W, Japan **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Ma YJ



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**